Peptide record

TPDB05956

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity standard
10 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB05956
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ToxinPred 3.0
standard
No
A 10-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
KIAKVALKAL
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C50H95N13O11
RNDCEQGHMFPSTWY
AK
1054.38
10.84
3
0
7
+3
-0.76
1.000
176.00
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
2
L
3
K
0
M
0
F
0
P
0
S
0
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 2 K: 3 M: 0 F: 0 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1
Chemical Descriptors
10 reviewed residue count
C50H95N13O11 sequence-only estimate (linear, free termini)
1054.38 sequence-only estimate (linear, free termini)
10.84 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
-0.76 sequence-only estimate (linear, free termini)
1.000 sequence-only estimate (linear, free termini)
Evidence Records 21 records
Evidence 1 Activity

Activity

MIC
Antibacterial
23.6 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resist
Evidence 2 Activity

Activity

MIC
Antibacterial
8.7 ug/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP DRAMP

Other

Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRS
Evidence 3 Activity

Activity

MIC
Antibacterial
14.4 ug/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

tivity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 4 Activity

Activity

MIC
Antibacterial
67.8 ug/mL

Target

Staphylococcus aureus MRSA

Source & Reference

dbAMP DRAMP

Other

IC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 5 Activity

Activity

MIC
Antifungal
23.6 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resist
Evidence 6 Activity

Activity

MIC
Antifungal
8.7 ug/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

dbAMP DRAMP

Other

Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRS
Evidence 7 Activity

Activity

MIC
Antifungal
14.4 ug/mL

Target

B. subtilis

Source & Reference

dbAMP DRAMP

Other

tivity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 8 Activity

Activity

MIC
Antifungal
67.8 ug/mL

Target

Staphylococcus aureus MRSA

Source & Reference

dbAMP DRAMP

Other

IC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 9 Activity

Activity

MIC
Antiparasitic
23.6 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets.
Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resist
Evidence 10 Activity

Activity

MIC
Antiparasitic
8.7 ug/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

DRAMP

Other

Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRS
Evidence 11 Activity

Activity

MIC
Antiparasitic
14.4 ug/mL

Target

B. subtilis

Source & Reference

DRAMP

Other

tivity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 12 Activity

Activity

MIC
Antiparasitic
67.8 ug/mL

Target

Staphylococcus aureus MRSA

Source & Reference

DRAMP

Other

IC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 13 Activity

Activity

MIC
Antiviral
23.6 ug/mL

Target

Escherichia coli ATCC 25922

Source & Reference

DRAMP

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets.
Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resist
Evidence 14 Activity

Activity

MIC
Antiviral
8.7 ug/mL

Target

Staphylococcus aureus ATCC 25923

Source & Reference

DRAMP

Other

Activity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRS
Evidence 15 Activity

Activity

MIC
Antiviral
14.4 ug/mL

Target

B. subtilis

Source & Reference

DRAMP

Other

tivity against E. coli ATCC 25922 (MIC 23.6 ug/mL), S. aureus ATCC 25923 (MIC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 16 Activity

Activity

MIC
Antiviral
67.8 ug/mL

Target

Staphylococcus aureus MRSA

Source & Reference

DRAMP

Other

IC 8.7 ug/mL), B. subtilis (MIC 14.4 ug/mL), and multidrug-resistant meticillin-resistant S. aureus MRSA (MIC 67.8 ug/mL).
Evidence 17 Activity

Activity

3% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
3% Hemolysis | 100 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Isolation and characterisation of a new antimicrobial peptide from the skin of Xenopus laevis. | Int J Antimicrob Agents | 2011
Evidence 18 Activity

Activity

8% Hemolysis
Toxicity
200 µg/mL
Hemolytic Cytotoxic
8% Hemolysis | 200 | µg/mL | target cell: Rabbit erythrocytes

Target

Rabbit erythrocytes

Source & Reference

NA
DBAASP
Isolation and characterisation of a new antimicrobial peptide from the skin of Xenopus laevis. | Int J Antimicrob Agents | 2011
Evidence 19 Activity

Activity

Toxicity
Hemolytic
NA | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 20 Activity

Activity

25% Cytotoxicity
Toxicity
256 µg/mL
Cytotoxic
25% Cytotoxicity | 256 | µg/mL | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
QSAR Reveals Decreased Lipophilicity of Polar Residues Determines the Selectivity of Antimicrobial Peptide Activity. | ACS Omega | 2024
Evidence 21 Activity

Activity

Toxicity
Hemolytic
Hemolytic_activity: [Ref.22014884]3.15% hemolytic activity at 100 µg/mL, 7.95% hemolytic activity at 200 µg/mL against rabbit red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Int J Antimicrob Agents. 2011 Dec 38(6):510-515.##J Biol Chem. 1991 Oct 15 266(29):19851-19857.